ACS Medicinal Chemistry Letters
Page 4 of 5
In summary, ditellurides exhibited substantially higher SI values
13 Pinton, S.; Luchese, C.; Stangherlin, E. C.; Roman, S. S.;
Nogueira, C. W. Diphenyl ditelluride induces neurotoxicity and
impairment of developmental behavioral in rat pups. J. Braz. Chem.
Soc. 2010, 21, 2130-2137.
14 Laden, B. P.; Porter, T. D. J. Inhibition of human squalene
monooxygenase by tellurium compounds: evidence of interaction
with vicinal sulfhydryls. Lipid Res. 2001, 42, 235-240.
15 Cunha, R. L.O.R.; Gouvea, I. E.; Juliano, L. A glimpse on
biological activities of tellurium compounds. An. Acad. Bras. Cienc.
2009, 81, 393-407.
than the reference drug and, in the most remarkable case, SI of the
compound LQ7 on the extracellular form of L. amazonensis exceeded
that of the reference drug by 74-fold. Moreover, LQ7 also exhibited
significant in vitro efficacy against intracellular amastigotes at sub-
micromolar concentration (IC50 = 0.5 ± 0.1 μmol L-1). In attempt to
better insight the activity, ditellurides with other substitution patterns
need to be investigated, as well as the mechanism of action of these
substances. These results suggest diaryl ditellurides as promising
scaffolds for development of new agents leishmaniasis treatment.
1
2
3
4
5
6
7
8
9
16 Yu, F.; Li, P.; Wang, B.; Han, K. Reversible near-infrared
fluorescent probe introducing tellurium to mimetic glutathione
peroxidase for monitoring the redox cycles between peroxynitrite and
glutathione in vivo. J. Am. Chem. Soc. 2013, 135, 7674 – 7680.
17 Shaaban, S.; Sasse, F.; Burkholz, T.; Jacob, C.; SAR studies on
hydropentalene derivatives- Important core units of biologically
active tetramic acid macrolactams and ptychanolides. Bioorg. Med.
Chem. 2014, 22, 3610-3619.
18 Zakrzewski, J.; Huras, B.; Kiełczewska, A.; Krawczyk, M.
Reactions of nitroxides 16. First nitroxides containing tellurium atom.
RSC Adv. 2016, 6, 98829-35.
19 Engman, L.; Al-Maharik, N.; McNaughton, M.; Birmingham,
A.; Powis, G. Thioredoxin reductase and cancer cell growth inhibition
by organotellurium antioxidants. Anti-Cancer Drugs. 2003, 14, 153–
161.
20 Doering, M.; Diesel, B.; Gruhlke, M. C. H.; Viswanathan, U.
M.; Manikova, D.; Chovanec, M.; Burkholz, T.; Slusarenko, A. J.;
Kiemer, A. K.; Jacob, C. Selenium- and tellurium-containing redox
modulators with distinct activity against macrophages: possible
implications for the treatment of inflammatory diseases. Tetrahedron.
2012, 68, 10577-10585.
21 Haller, W. S.; Irgolic, K. J. Diaryl Ditellurides from grignard
reagents and elemental tellurium. J. Organometal. Chem.1972, 38, 97
– 103.
22 Wirth, T.; Fragale, G. Asymmetric addition reactions with
optimized selenium electrophiles. Chem. Eur. J. 1997, 3, 1894 –
1902.
23 Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A.
R. Vogel’s Textbook of Practical Organic Chemistry, 5ª ed., Prentice
Hall: London, 1994.
24 Pietrasiak, E. Togni, A. Synthesis and characterization of
fluorinated hypervalent tellurium derivatives. Organometallics 2017,
36, 3750−3757.
25 Aponte, J. C.; Castillo, D.; Estevez, Y.; Gonzalez, G.; Arevalo,
J.; Hammond, G. B.; Sauvain, M. In vitro and in vivo anti-Leishmania
activity of polysubstituted synthetic chalcones. Bioorg. Med. Chem.
Lett. 2010, 20, 100-103.
26 Sudha, N.; Singh, H. B. Intramolecular coordination in tellurium
chemistry. Coord. Chem. Rev. 1994, 135, 469-515.
27 Mukherjee, A. J.; Zade, S. S.; Singh, H. B.; Sunoj, R. B.
Organoselenium chemistry: role of intramolecular interactions. Chem.
Rev. 2010, 110, 4357–4416.
28 Somanna, A.; Mundodi, V.; Gedamu, L. Functional analysis of
cathepsin B-like cysteine proteases from Leishmania donovani
complex. Evidence for the activation of latent transforming growth
factor beta. J Biol Chem. 2002, 277, 25305–25312.
29 Piovan, L.; Alves, M. F. M.; Juliano, L.; Bromme, D.; Cunha, R.
L. O. R.; Andrade, L. H. Structure-activity relationships of
hypervalent organochalcogenanes as inhibitors of cysteine cathepsins
V and S. Bioorg. Med. Chem. 2011, 19, 2009-2014.
ASSOCIATED CONTENT
Supporting Information
Synthetic procedures, biological assays protocols and NMR (1H,
13C and 125Te) data of compounds are available in Supporting
Information (PDF).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
AUTHOR INFORMATION
Corresponding Author
*Tel.: +55-041-3361-3178; e-mail: lpiovan@quimica.ufpr.br
ACKNOWLEDGMENT
The authors would like to thank National Council for Scientific
and Technological Development (CNPq, Brazil, Proc.
456834/2014) and Coordination for the Improvement of Higher
Level Personnel (CAPES) for financial support and fellowships.
REFERENCES
1 World Health Organization: Weekly Epidemiological Record
(WER).
2016,
91,
285–296.
2 Séguin, O.; Descoteaux, A.; Leishmania, the phagosome, and host
responses: The journey of a parasite. Cell Immunol. 2016, 309, 1-6.
3 Monge-Maillo, B.; López-Vélez, R. Miltefosine for visceral and
cutaneous leishmaniasis: drug characteristics and evidence-based
treatment recommendations. Clin. Infect. Dis. 2015, 60, 1398-1404.
4 Dorlo, T.P.; Balasegaram, M.; Beijnen, J.H.; de Vries, P.J.
Miltefosine: a review of its pharmacology and therapeutic efficacy in
the treatment of leishmaniasis. J. Antimicrob. Chemother. 2012, 67,
2576-2597.
5 Sunyoto, T.; Potet, J.; Boelaert, M. Why miltefosine—a life-
saving drug for leishmaniasis—is unavailable to people who need it
the most. BMJ Glob Health, 2018, 3, e000709.
6 Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug resistance in
leishmaniasis. Clin Microbiol Rev. 2006, 19, 111-126.
7 Yasinzai, M.; Khan, M.; Nadhman, A.; Shahnaz, G. Drug
resistance in leishmaniasis: current drug-delivery systems and future
perspectives. Future Med Chem. 2013, 5, 1877–1888.
8 Lima, C. B. C.; Arrais-Silva, W. W.; Cunha, R. L. O. R.; Giorgio,
S.
A novel organotellurium compound (RT-01) as a new
antileishmanial agent. Korean J. Parasitol. 2009, 47, 213-218.
9 Pimentel, I. A. S.; Paladi, C. S.; Katz, S.; Judice, W. A. S.; Cunha,
R. L. O. R.; Barbiéri, C. In vitro and in vivo activity of an organic
tellurium compound on Leishmania (Leishmania) chagasi. PLoS One,
2012, 7, e48780-7.
10 Vishwakarma, P.; Parmar, N.; Chandrakar, P.; Sharma, T.;
Kathuria, M.; Agnihotri, P. K.; Siddiqi, M. I.; Mitra, K.; Ka, S.;
Ammonium trichloro [1,2-ethanediolato-O,O′]-tellurate cures
experimental visceral leishmaniasis by redox modulation of
Leishmania donovani trypanothione reductase and inhibiting host
integrin linked PI3K/Akt pathway. CMLS. 2018, 75, 563–588.
11 Comasseto, J. V. Selenium and tellurium chemistry: historical
background. J. Braz. Chem. Soc. 2010, 21, 2027-2031.
12 Nogueira, C. W.; Zeni, G.; Rocha, J. B. T. Organoselenium and
organotellurium compounds: toxicology and pharmacology. Chem.
Rev. 2004, 104, 6255 - 6284.
ACS Paragon Plus Environment